KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) Leases (2019 - 2025)

Aquestive Therapeutics has reported Leases over the past 7 years, most recently at $4.6 million for Q4 2025.

  • Quarterly results put Leases at $4.6 million for Q4 2025, down 10.83% from a year ago — trailing twelve months through Dec 2025 was $4.6 million (down 10.83% YoY), and the annual figure for FY2025 was $4.6 million, down 10.83%.
  • Leases for Q4 2025 was $4.6 million at Aquestive Therapeutics, down from $4.8 million in the prior quarter.
  • Over the last five years, Leases for AQST hit a ceiling of $5.9 million in Q1 2023 and a floor of $2.1 million in Q3 2022.
  • Median Leases over the past 5 years was $5.0 million (2025), compared with a mean of $4.4 million.
  • Biggest five-year swings in Leases: decreased 28.21% in 2022 and later surged 170.73% in 2023.
  • Aquestive Therapeutics' Leases stood at $2.7 million in 2021, then surged by 91.23% to $5.2 million in 2022, then increased by 6.64% to $5.6 million in 2023, then dropped by 6.75% to $5.2 million in 2024, then decreased by 10.83% to $4.6 million in 2025.
  • The last three reported values for Leases were $4.6 million (Q4 2025), $4.8 million (Q3 2025), and $4.9 million (Q2 2025) per Business Quant data.